NCT06619808View on ClinicalTrials.gov

Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

NARecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

August 1, 2026

Study Completion Date

August 31, 2026

Conditions
Metabolic Dysfunction-associated Steatotic Liver DiseaseHepatic SteatosisNon-alcoholic Fatty Liver Diseases
Interventions
PROCEDURE

Hyperbaric oxygen therapy

Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).

Trial Locations (1)

210000

RECRUITING

General Hospital of Eastern Theater Command, Nanjing

All Listed Sponsors
lead

Jinling Hospital, China

OTHER